Atopic Dermatitis

An expert in the management of skin conditions highlights the case of a 45-year-old female with severe pruritus, erythematous rash, and lichenification across multiple body areas, worsened by recent work-related stress from a promotion. Dr. Lio offers insights into managing such patients and shares practical tips for a streamlined prescription process.

Peter Lio, MD, presents the case of a 56-year-old female with a history of severe atopic dermatitis and very dry skin. Dr. Lio discusses the significance of accurate disease diagnosis, tools for assessing severity, and the array of treatment options available for this patient. He emphasizes the importance of shared decision-making in managing the condition.

The study findings were presented in a poster at the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Tapinarof is showing promise in the landscape of dermatological treatment. Adelaide Hebert, MD, FAAD, recently served as an investigator for 2 studies presented at the European Academy of Dermatology and Venereology (EADV) Congress and discussed key points with Raj Chovatiya, MD, PhD.

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options. She also reviews the significance of patient assistance programs in facilitating patient access to and affordability of pharmaceutical therapies.

Tina Bhutani-Jacques, MD, presents the case of a 28-year old male with atopic dermatits, wherein the patient attributes his flares to his housing conditions. She discusses the role of patient counseling, shared decision making, and sustained disease control in the management of patients suffering from this condition.

Pusan National University published the review in light of the growing body of JAK inhibitors in the AD space.

An expert in skin condition management discusses the case of a 13-year-old male with a prolonged history of AD and early-onset food allergies. Emphasizing the challenges of the steroid treatment cycle, the expert provides insights into integrating parental preferences for "natural" agents alongside effective pharmaceutical options. Additionally, the discussion explores strategies for communicating treatment mechanisms to patients and fostering collaborative engagement in the treatment selection process.

TJ Chao, MPAS, PA-C, examines the case of an 18-year-old female with persistent AD, wherein the patient attributes her flares to her housing conditions. He discusses her treatment plan and addresses the challenges posed by red face syndrome induced by dupilumab, while commenting on how the panel managed patient expectations, treatment preferences, and sustained disease control.

Adbry (tralokinumab-LDRM) is now the first and only FDA-approved biologic for AD binding to and inhibiting IL-13.

Catch up on coverage from this week's virtual Revolutionizing Atopic Dermatitis and Revolutionizing Vitiligo conferences.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the newer treatments in AD, highlighting the positive impact these agents have had in managing the disease.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the current treatment landscape of atopic dermatitis (AD), as well as key factors when selecting treatment for patients with the disease.

Biolojic’s BD9 is a dual specific antibody that can block both Thymic stromal lymphopoietin and IL-13.

At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."

The poster was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.

Dr Lal, an expert in dermatology, presents the case of a 45-year-old female with a history of childhood AD marked by severe symptoms. He recaps a panel conversation on the approach to treatment, emphasizing the importance of initiating effective and long-lasting treatment options for optimal relief.

Karan Lal, DO, MS, FAAD, discusses a case involving a 4-year-old male with atopic dermatitis, covering FDA-approved treatments for this age group, strategies for tapering and stopping treatment, the impact of the atopic march, and challenges with treatment prior authorizations.

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

From the December cover feature: Christopher Bunick, MD, PhD; Aaron Drucker, MD, ScM; and Mona Shahriari, MD, share their thoughts on AAD’s updated atopic dermatitis guidelines.

Jennifer Etienne shared her experiences during the shared decision-making patient panel of the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

A poster from the 2023 Revolutionizing Atopic Dermatitis Conference revealed a link between AD, impaired oral health, and oral dysbiosis.

Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.

Approximately 76% of patients reported being "satisfied," while 18% reported they were "very satisfied" with treatment.

KT-474 is a first-in-class, investigational IRAK4 degrader.